ASCO 2024 Abstract for Trial #22-09

A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.

Wednesday, June 19, 2024

Dr. Minal Barve

Read the Story Here

Click the above link to view the abstract.

ASCO 2024 Poster for Trial 22-09

ASCO 2024 Poster for Trial 22-09

Click here to view the ASCO 2024 Poster for Trial 22-09 in Full-Size.

Related Abstracts

Discover more abstracts for our trials.

Preliminary Clinical Activity of RMC-6236, a First-in-Class, RAS-Selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC)

Aug 23, 2024

Dr. Minal Barve

STX-478, a mutant-selective PI3Kαinhibitor clinical candidate with a best-in-class profile: Pharmacology and therapeutic activity as monotherapy and in combination in breast cancer xenograft models

Aug 21, 2024

Dr. Douglas Orr

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression

Aug 21, 2024

Dr. Minal Barve
See All Posts